Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 395-400

  Ranieri, E ^a,b   Gigante, M ^b   Storkus, W J ^b   Gesualdo, L ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Renal cell carcinoma; T cell responses; TAA; Vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FLUOROURACIL; GAMMA INTERFERON; HLA A24 ANTIGEN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; ISOTRETINOIN; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOGENICITY; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; MONOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; HUMANS; KIDNEY NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 33846809092     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03305.x     Document Type: Short Survey

References (48)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Rini BI, Campbell SC, Rathmell WK. Renal cell carcinoma. Curr Opin Oncol 2006; 18:289-96.
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
4. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763-71.
5. Whang YE, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2003; 15:213-6.
6. Kawai K, Saijo K, Oikawa T, Ohno T, Akaza H. Enhancement of T cell proliferative response against autologous cancer cells of a metastatic renal cell carcinoma patient after unexplained regression. Int J Urol 2004; 11:1130-2.
7. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44:65-75.
8. Finke JH, Kierstead LS, Ranieri E, Storkus WJ. Immunologic response to renal carcinoma. In: Bukowski RM, Novick AC, eds. Renal cell carcinoma, molecular biology, immunology and clinical management. Totowa, NJ: Humana Press, Inc., 2000:39-62.
9. Mellman I, Steinman RM. Dendritic cells: specialized and regulate antigen processing machines. Cell 2001; 106:255-8.
10. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2:585-9.
11. Dadabayev AR, Sandel MH, Menon AG et al. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother 2004; 53:978-86.
12. Turtle CJ, Hart DN. Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets 2004; 5:17-39.
13. Bell D, Chomarat P, Banchereau J et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190:1417-26.
14. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41.
15. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2-therapy. J Clin Oncol 1995; 13:688-96.
16. Choromat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes form dendritic cells to macrophages. Nat Immunol 2000; 1:510-4.
17. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424-30.
18. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesionmolecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3:2451-8.
19. Nabel GJ. Genetic, cellular and immune approaches to disease therapy: past and future. Nat Med 2004; 10:135-41.
20. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537-46.
21. Malone CC, Schiltz PM, Mackintosh AD, Beutel LD, Heinemann FS, Dillman RO. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother Radiopharm 2001; 16:381-90.
22. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521-9.
23. Uzzo RG, Cairns P, Al-Saleem T et al. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003; 30:423-36.
24. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-82.
25. van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 2005; 16:709-17.
26. Frankenberger B, Regn S, Geiger C et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 2005; 23:166-74.
27. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369-76.
28. Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51:637-44.
29. Kugler A, Stulher G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332-6.
30. Kugler A, Stuhler G, Walden P et al. Retraction: regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2003; 9:1221.
31. Grabmaier K, Vissers JL, de Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85:865-70.
32. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA, Belldegrun AS. G250: a carboic anydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7:109-15.
33. Shimizu K, Uemura H, Yoshikawa M et al. Induction of antigen specific cellular immunity by vaccination from MN/CA IX in renal cell carcinoma. Oncol Rep 2003; 10:1307-11.
34. Uemura H, Fujimoto K, Tanaka M, et al. A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12:1768-75.
35. Su Z, Dannul J, Reiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127-33.
36. Geiger C, Regn S, Weinzierl A, Noessner E, Schendel DJ. A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J Transl Med 2005; 3:29.
37. Takahashi T, Kuniyasu Y, Toda M et al. Immunological self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10:1969-80.
38. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
39. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272-6.
40. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
41. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33.
42. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063-74.
43. Berd D, Maguire HC, Mastrangelo MJ. Potentiation of human cll-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44:5439-43.
44. Holtl L, Ramoner R, Zelle-Rieser C et al. Allogenic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54:663-70.
45. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen-presenting function of dendritic cells. Curr Opin Immunol 1997; 9:10-6.
46. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14:461-70.
47. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:119-34.
48. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. Alpha-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64:5934-7.